MedTrace Logo

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

NCT06129084 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2025-12-15

No results posted yet for this study

Summary

A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer.

In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result.

Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.

Conditions

  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma

Interventions

GENETIC

FGFR Testing

Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.

Sponsors & Collaborators

  • Vancouver Prostate Centre

    collaborator OTHER

  • Lady Davis Institute

    collaborator OTHER

  • Bladder Cancer Canada

    collaborator UNKNOWN

  • Bernie Eigl

    lead OTHER

Principal Investigators

  • Bernhard Eigl · British Columbia Cancer Agency

  • Alexander Wyatt · Vancouver Prostate Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2025-09-15
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06129084 on ClinicalTrials.gov